Allogene Therapeutics Inc [ALLO] stock is trading at $1.51, down -2.58%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ALLO shares have gain 5.59% over the last week, with a monthly amount glided 22.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on October 10, 2025, when JP Morgan downgraded its rating to an Underweight. Previously, Citizens JMP downgraded its rating to Mkt Perform on May 14, 2025. On March 14, 2025, upgrade upgraded it’s rating to Mkt Outperform but maintained its price target of $5 on the stock. Piper Sandler initiated its recommendation with a Overweight and recommended $11 as its price target on May 31, 2024. JMP Securities downgraded its rating to Mkt Perform for this stock on January 05, 2024. In a note dated January 05, 2024, Guggenheim downgraded a Neutral rating on this stock.
Allogene Therapeutics Inc [ALLO] stock has fluctuated between $0.86 and $3.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.51 at the most recent close of the market. An investor can expect a potential return of 1820.53% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.58 and Total Capital is -0.56. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4850 points at the first support level, and at 1.4600 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5500, and for the 2nd resistance point, it is at 1.5900.
Ratios To Look Out For
For context, Allogene Therapeutics Inc’s Current Ratio is 8.19. Also, the Quick Ratio is 8.19, while the Cash Ratio stands at 1.19.
Transactions by insiders
Recent insider trading involved Beneski Benjamin Machinas, SVP, Chief Technical Officer, that happened on Nov 17 ’25 when 786.0 shares were sold. Officer, Beneski Benjamin Machinas completed a deal on Nov 17 ’25 to buy 786.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Parker Geoffrey M. sold 36744.0 shares on Oct 21 ’25.
